XML 39 R26.htm IDEA: XBRL DOCUMENT
v3.26.1

License Agreements - CD47 License (Details) - USD ($) |  | 3 Months Ended | 12 Months Ended |  |
--- | --- | --- | --- | --- | ---
Feb. 20, 2026 | Mar. 31, 2026 | Mar. 31, 2025 | Dec. 31, 2024 | Dec. 31, 2025 | Oct. 31, 2022
License Agreements |  |  |  |  |  |
Research and development expense related to the CD47 License |  | $ 400,000 |  | $ 2,685,334 |  |
CD47 License agreement with InnoBation |  |  |  |  |  |
License Agreements |  |  |  |  |  |
Percentage of activities completed |  | 40.00% |  |  |  |
Prepaid research and development costs |  | $ 600,000 |  |  | $ 0 |
Research and development expense related to the CD47 License |  | $ 400,000 | $ 0 |  |  |
CD47 License agreement with InnoBation | Curis Biotech Holdings LLC | Class A Member Units |  |  |  |  |  |
License Agreements |  |  |  |  |  |
Number of member units exchange for license rights to develop |  |  |  |  |  | 78,555,554
Value of membership interest offset to additional paid-in capital |  |  |  |  |  | $ 800,000
CD47 License agreement with InnoBation | Innobation Bio Co. Ltd |  |  |  |  |  |
License Agreements |  |  |  |  |  |
Company issued a payment | $ 1,000,000 |  |  |  |  |

X
- Definition The estimated percentage of activities completed by the company as per agreement. + References No definition available. + Details
Name: | limn_EstimatedPercentageOfActivitiesCompleted
Namespace Prefix: | limn_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Value of membership interest exchange for license fees being offset to additional paid-in capital. + References No definition available. + Details
Name: | limn_LicenseRightsValueOfUnitsOffsetFromAdditionalPaidInCapital
Namespace Prefix: | limn_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Number of member units exchanged as a consideration for license rights to develop, market and sell YN1203, InnoBation Bio CAR NK biomarkers, including devices, compounds and products used to detect analyte in body or tissue. + References No definition available. + Details
Name: | limn_NumberOfUnitsExchangeForLicenseRights
Namespace Prefix: | limn_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | instant

X
- Definition Amount of payment made for costs associated with clinical trials. + References No definition available. + Details
Name: | limn_PaymentForCostsAssociatedWithClinicalTrials
Namespace Prefix: | limn_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of prepaid research and development classified as current. + References No definition available. + Details
Name: | limn_PrepaidResearchAndDevelopmentExpenseCurrent
Namespace Prefix: | limn_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 808 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1 + Details
Name: | us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 220 -SubTopic 40 -Name Accounting Standards Codification -Section 55 -Paragraph 18 -Publisher FASB -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18 Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 220 -SubTopic 40 -Name Accounting Standards Codification -Section 55 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14 Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1 Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 912 -SubTopic 730 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1 + Details
Name: | us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=limn_Cd47LicenseAndDevelopmentAgreementWithInnobationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=limn_CurisBiotechHoldingsLlcMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_CapitalUnitsByClassAxis=us-gaap_CapitalUnitClassAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=limn_InnobationBioCo.LtdMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |